GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alumis ALMS · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.55

+8.62%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$24.1m

FY2022FY2025

Net income

−$243.3m

FY2022FY2025

Free cash flow

−$370.2m

FY2022FY2025

Shareholders' equity

$301.3m

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue$24.1m———
Gross profit$20.6m−$3.2m−$1.3m−$250,000
Research and development$386.0m$265.6m$137.7m$101.1m
Operating income−$427.2m−$300.8m−$158.2m−$113.8m
Net income−$243.3m−$294.2m−$155.0m−$111.9m
Diluted earnings per share-2.32-5.47-2.99-14.93

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets$411.9m$341.0m$89.6m$108.2m
Cash and short-term investments$308.5m$288.3m$49.0m$92.9m
Total liabilities$110.6m$80.9m$428.9m$303.4m
Debt$4.7m———
Shareholders' equity$301.3m$260.1m−$339.3m−$195.2m
Shares outstanding105m54m52m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−$369.5m−$255.1m−$130.0m−$107.7m
Capital spending−$653,000−$1.7m−$4.5m−$2.4m
Free cash flow−$370.2m−$256.8m−$134.5m−$110.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.7m$1.7m$1.9m$2.1m$2.7m$17.4m$3.0m—
Gross profit$1.7m$870,000$1.9m$2.1m$2.7m$17.4m−$820,000−$814,000
Operating income−$148.9m−$98.4m−$96.4m−$115.3m−$140.5m−$101.5m−$98.6m−$98.4m
Net income−$142.2m−$93.1m−$92.9m−$110.8m$59.3m−$99.0m−$94.8m−$93.1m
Diluted earnings per share-1.11-0.73-0.89-1.060.57-0.95-1.76-1.73
Cash from operations−$81.0m−$87.0m−$71.0m−$110.0m−$106.0m−$80.0m−$74.0m−$83.0m
Total assets$560.6m$671.6m$411.9m$488.0m$610.9m$261.3m$341.0m$412.6m
Cash and short-term investments$502.3m$522.9m$308.5m$377.7m$486.3m$208.7m$288.3m$361.9m
Debt$4.8m$4.4m$4.7m$4.4m$4.1m$2.5m$1.6m$1.5m
Shareholders' equity$452.2m$567.0m$301.3m$384.8m$485.3m$168.3m$260.1m$348.4m

Financial ratios

Data as of 23 Oct 2026

FY2025FY2024FY2023FY2022
Gross margin85.5%———
Operating margin-1047.3%———
Net margin-1011.7%———
Return on equity-80.8%-113.1%45.7%57.3%
Return on assets-59.1%-86.3%-173.0%-103.5%
Free cash flow yield-51.7%-69.1%-35.5%—
Earnings growth-17.3%89.8%38.5%—
Current ratio4.34x6.01x2.56x7.68x
Debt to equity0.02x0.01x-0.01x-0.01x
Equity ratio73.1%76.3%-378.6%-180.5%
R&D as a share of sales1605.0%———
Buybacks as a share of market value-94.8%-3.7%——

Growth per year

Compound annual rate

3 years5 years10 years
Operating income55.4%——
Net income29.5%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-1.8-0.6
Price to sales18.4—

Market value over time

28 Jun 2024 to 22 Oct 2026, in USD

$689.5m$870.8m

Share price return

Finished calendar years

20252024
Return31%-37%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.